Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Cycloserine Augmentation of ERP for OCD
NCT00257361Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Jul 2005
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in obsessive compulsive disorder (OCD), sponsored by University of Florida. Primary endpoint: Yale-Brown Obsessive Compulsive Scale. Planned start Jul 2005; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00257361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257361.